Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John A. Smoliga is active.

Publication


Featured researches published by John A. Smoliga.


Journal of Pharmaceutical Sciences | 2009

Drug–Excipient Complexation in Lipid Based Delivery Systems: An Investigation of the Tipranavir-1,3-Dioctanolyglycerol Complex

Shirlynn Chen; Mayur S. Dudhedia; Zeren Wang; Richard T. Darrington; Toby Tamblyn; John A. Smoliga; Paul-James Jones; Steven L. Krill

This report describes the solubility properties of a poorly soluble drug-excipient complex in a lipid based formulation. Tipranavir (TPV) was used as the model drug and 1,3-dioctanoylglycerol (DOG) as the excipient. The TPV-DOG complex was prepared by dissolving TPV and DOG in ethanol at 60 degrees C followed by evaporation of ethanol. The formation of the complex with a 4:1 TPV-to-DOG molar ratio was confirmed by XRPD, DSC, and NMR. At 25 degrees C, total solubility of TPV decreased with increasing DOG concentration. The solubility properties of the TPV-DOG complex can be described by two simultaneous equilibria: a liquid-solid phase equilibrium of the complex and a species equilibrium among the various species in the liquid phase. A model equation was derived accordingly with two parameters, the intrinsic solubility of the complex (S(o)), and the solution complex constant (K(41)). The model was in good agreement with experimental results. The values of S(o) and K(41) are 0.0186 +/- 0.0025 (M) and 21.97 +/- 7.19 (1/M(4)), respectively. The equation can successfully predict the concentrations of total and free TPV as a function of DOG in the formulation. The approach developed provides a useful tool for rationale selection of excipients and their levels to avoid drug precipitation in lipid based formulations.


Journal of Pharmaceutical and Biomedical Analysis | 2010

Study and characterization of crystalline hydrate/polymorph forms of 5,11-dihydro-11-ethyl-5-methyl-8-(2-(1-oxido-4-quinolinyl)ethyl-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepin-6-one by solid-state NMR and solution NMR.

Nina C. Gonnella; John A. Smoliga; Scot Campbell; Carl A. Busacca; Michael Kenneth Cerreta; Richard J. Varsolona; Daniel L. Norwood

A novel inhibitor of reverse transcriptase was studied by solid-state NMR. Three phases of the compound were examined which included the dihydrate and two anhydrous polymorphs (Form I and Form III). By correlating (1)H and (13)C solution NMR with the solid-state (13)C NMR CP/MAS and CPPI spectral editing experiments, comparative (13)C assignments were made for each phase. Polymorphs of Form I and Form III and the dihydrate were easily distinguished based upon chemical shift patterns of the carbon resonances. The (1)H spin-lattice relaxation times were also measured for each phase which provided information on the mobility and relative crystallinity. The (13)C ssNMR spectrum of Form I showed the presence of a minor component identified as the dihydrate. Weight/percent quantitation of major and minor components in Form I was obtained from integrated intensities of a 50:50 mixture containing weighed amounts of Form I and the pure dihydrate. Comparison of the ssNMR and X-ray powder diffraction techniques is discussed.


Archive | 2011

Crystalline phases of a potent HCV inhibitor

Michael Kenneth Cerreta; John A. Smoliga; Richard J. Varsolona


Organic Process Research & Development | 2013

Development and Characterization of a Cocrystal as a Viable Solid Form for an Active Pharmaceutical Ingredient

Soojin Kim; Zhibin Li; Yin-Chao Tseng; Herbert Nar; Earl Spinelli; Richard J. Varsolona; Jonathan T. Reeves; Heewon Lee; Jinhua J. Song; John A. Smoliga; Nathan K. Yee; Chris H. Senanayake


Asian Journal of Organic Chemistry | 2012

Practical Large-Scale Synthesis of the Hepatitis C Virus Protease Inhibitor BI 201335

Carl A. Busacca; Xudong Wei; Nizar Haddad; Suresh R. Kapadia; Jon C. Lorenz; Anjan Saha; Richard J. Varsolona; Thilo Berkenbusch; Scot C. Campbell; Vittorio Farina; XuWu Feng; Nina C. Gonnella; Nelu Grinberg; Paul-James Jones; Heewon Lee; Zhibin Li; Oliver Niemeier; Wendelin Samstag; Max Sarvestani; Juergen Schroeder; John A. Smoliga; Earl Spinelli; Jana Vitous; Chris H. Senanayake


Archive | 2004

Polymorph of birb 796, a p38map kinase inhibitor

John A. Smoliga; Jana Vitous


Archive | 2006

Stable Sertraline Hydrochloride Formulation and Method

Julia J. Economou; Andrea M. Mcphillips; John A. Smoliga; Randall Scott Wilson


Archive | 2005

Crystalline forms of 5, 11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepin-6-one

Carl A. Busacca; Michael Kenneth Cerreta; Richard J. Varsolona; John A. Smoliga; Jon C. Lorenz; Jana Vitous


Leachables and Extractables Handbook: Safety Evaluation, Qualification, and Best Practices Applied to Inhalation Drug Products | 2012

Foreign Particulate Matter: Characterization and Control in a Quality‐By‐Design Environment

James R. Coleman; John A. Robson; John A. Smoliga; Cornelia B. Field


Archive | 2004

Phases cristallines d'un inhibiteur puissant du vhc

Michael Kenneth Cerreta; John A. Smoliga; Richard J. Varsolona

Collaboration


Dive into the John A. Smoliga's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge